193 related articles for article (PubMed ID: 30317360)
1. The glycaemic sixer [glycaemic hexad].
Kalra S
J Pak Med Assoc; 2018 Oct; 68(10):1541-1542. PubMed ID: 30317360
[TBL] [Abstract][Full Text] [Related]
2. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
Zenari L; Marangoni A
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516
[TBL] [Abstract][Full Text] [Related]
3. Which patients should be evaluated for blood glucose variability?
Candido R
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():9-12. PubMed ID: 24034514
[TBL] [Abstract][Full Text] [Related]
4. Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial.
Zhou JJ; Koska J; Bahn G; Reaven P
Diab Vasc Dis Res; 2019 Mar; 16(2):178-185. PubMed ID: 31014099
[TBL] [Abstract][Full Text] [Related]
5. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
[TBL] [Abstract][Full Text] [Related]
6. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
Cavalot F
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():3-8. PubMed ID: 24034513
[TBL] [Abstract][Full Text] [Related]
7. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
8. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
9. Daily glycaemic variability: benefits of optimal control.
Cavalot F
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():1-2. PubMed ID: 24034512
[No Abstract] [Full Text] [Related]
10. The gluco-phenotype.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Jan; 66(1):118-9. PubMed ID: 26712197
[TBL] [Abstract][Full Text] [Related]
11. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B
Diabetes Res Clin Pract; 2015 Apr; 108(1):179-86. PubMed ID: 25661664
[TBL] [Abstract][Full Text] [Related]
12. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Rosenstock J; Rood J; Cobitz A; Huang C; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
[TBL] [Abstract][Full Text] [Related]
13. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.
Hassanein M; Echtay AS; Malek R; Omar M; Shaikh SS; Ekelund M; Kaplan K; Kamaruddin NA
Diabetes Res Clin Pract; 2018 Jan; 135():218-226. PubMed ID: 29183844
[TBL] [Abstract][Full Text] [Related]
14. Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials.
Kautzky-Willer A; Kosi L; Lin J; Mihaljevic R
Diabetes Obes Metab; 2015 Jun; 17(6):533-540. PubMed ID: 25678212
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ramadan fasting on glycaemic parameters & body mass index in type II diabetic patients: A meta-analysis.
Aydin N; Kul S; Karadağ G; Tabur S; Araz M
Indian J Med Res; 2019 Dec; 150(6):546-556. PubMed ID: 32048618
[TBL] [Abstract][Full Text] [Related]
16. Assessment of glycaemic control in patients with diabetes mellitus on insulin therapy.
Mukherjee JJ; Majumdar S; Ray S
J Indian Med Assoc; 2013 Nov; 111(11):761-5. PubMed ID: 24968486
[No Abstract] [Full Text] [Related]
17. Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes.
Zhang Y; Zhao Z; Wang S; Zhu W; Jiang Y; Sun S; Chen C; Wang K; Mu L; Cao J; Zhou Y; Gu W; Hong J; Wang W; Ning G
Diabetes Metab Res Rev; 2017 Oct; 33(7):. PubMed ID: 28609547
[TBL] [Abstract][Full Text] [Related]
18. Insulin during pregnancy, labour and delivery.
de Valk HW; Visser GH
Best Pract Res Clin Obstet Gynaecol; 2011 Feb; 25(1):65-76. PubMed ID: 21186142
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
20. How can we monitor glycaemic variability in the clinical setting?
Inchiostro S; Candido R; Cavalot F
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():13-6. PubMed ID: 24034515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
